CN103006695A - Intraocular perfusate and preparation method thereof - Google Patents
Intraocular perfusate and preparation method thereof Download PDFInfo
- Publication number
- CN103006695A CN103006695A CN2012105458411A CN201210545841A CN103006695A CN 103006695 A CN103006695 A CN 103006695A CN 2012105458411 A CN2012105458411 A CN 2012105458411A CN 201210545841 A CN201210545841 A CN 201210545841A CN 103006695 A CN103006695 A CN 103006695A
- Authority
- CN
- China
- Prior art keywords
- hydrogen
- balanced salt
- solution
- intraocular irrigating
- salt solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to intraocular perfusate and a preparation method thereof. The intraocular perfusate comprises medical common ophthalmology balanced salt solution, wherein the medically common ophthalmology balanced salt solution is hydrogen saturate intraocular perfusate. The invention provides intraocular perfusate which is applied to a vitrectomy operation and can effectively prevent cataract after the vitrectomy operation and a preparation method thereof.
Description
Technical field
The invention belongs to field of medicaments, relate to a kind of intraocular irrigating solution and preparation method thereof, relate in particular to saturated intraocular irrigating solution of a kind of hydrogen and preparation method thereof.
Background technology
Vitrectomy is one of ophthalmology routine operation, is used for the treatment of the multiple ocular disease such as detachment of retina, vitreous hemorrhage.In operation process, be the balance intraocular pressure, the use of intraocular irrigating solution is essential.Conventional intraocular irrigating solution is the ophthalmology balanced salt solution, this solution the preparation and use procedure in the saturation of the air, contain higher partial pressure of oxygen (21.2kPa), in operation process, along with the removal of vitreous body tissue, its iris action for the disperse of retinal vessel oxygen is eliminated, use the intraocular irrigating solution that contains the higher oxygen dividing potential drop in the art simultaneously, thereby crystalline lens is exposed in the high keto sectional pressure environment, accelerates lenticular oxidative damage, induce the cataractous generation of postoperative.
Summary of the invention
In order to solve the above-mentioned technical problem that exists in the background technology, the invention provides a kind of intraocular irrigating solution that also can effectively prevent the cataract in vitretomized eyes generation for Vitrectomy and preparation method thereof.
Technical solution of the present invention is: the invention provides a kind of intraocular irrigating solution, comprise ophthalmology balanced salt solution medically commonly used, its special character is: the described ophthalmology balanced salt solution of medically commonly using is the saturated intraocular irrigating solution of hydrogen.
A kind of preparation method be used to realizing above-mentioned intraocular irrigating solution, its special character is: said method comprising the steps of:
1) the ophthalmology balanced salt solution of medically commonly using of bag taking dress;
2) with the air in the packed balanced salt solution with aseptic needle tubing from the sucking-off of the soft bag of infusion liquid dosing mouth;
3) slowly pass into high-purity hydrogen until till the soft bag of this infusion liquid is complete expansion, can't passes into unnecessary gaseous state again by pinprick place, aseptic needle tubing place is disposable;
4) the soft bag of sterile sealing infusion liquid dosing mouth;
5) the resulting liquid of step 3) is placed the environment under high pressure persistent pressure of 0.5-0.6Mpa, obtain the saturated intraocular irrigating solution of hydrogen.
Above-mentioned steps 3) high-purity hydrogen is that purity is not less than 99.99% hydrogen in.
Above-mentioned steps 4) time of pressurization is not less than 4 hours in.
Above-mentioned steps 4) also comprise afterwards:
6) place 4 ℃ to keep in Dark Place the saturated intraocular irrigating solution of the resulting hydrogen of step 5).
Advantage of the present invention is:
The invention provides a kind of intraocular irrigating solution and preparation method thereof, be about to replace with hydrogen saturated with the saturation of the air in traditional ophthalmology balanced salt solution, hydrogen is a kind of gas nontoxic to histiocyte, can free disperse enter cell membrane, enter hydrogen and the intracellular harmful substance hydroxy radical (OH of cell membrane
-)---the reactive oxygen species that a kind of toxicity is stronger, neutralization reaction occurs, directly generate H
2O, thus this material reduced for histiocytic oxidative injury.In vitrectomy, no matter be that vitreous body is organized in the excision in the art, or the use of normal partial pressure of oxygen intraocular irrigating solution, all so that crystalline lens is exposed to higher partial pressure of oxygen environment, reactive oxygen species content increases in the lens epithelial cells thereby make, cell generation oxidative damage brings out cataractous formation.The method of using high pressure to expose among the present invention increases the dissolubility of hydrogen in solution, forms the hydrogen saturated solution, has greatly increased the hydrogen content in the infusion liquid.Hydrogen is brought into along with the use of infusion liquid around the crystalline lens, and directly disperse enters lens epithelial cells, reacts with harmful hydroxy radical in the cell, alleviates the cellular oxidation damage, can effectively prevent the generation of cataract in vitretomized eyes.
Description of drawings
Fig. 1 is that intraocular irrigating solution involved in the present invention prevents cataract in vitretomized eyes mechanism sketch map;
Fig. 2 is that hydrogen saturated saline solution lumbar injection is intervened mice selenium cataract experiment photo;
The specific embodiment
The preparation of embodiment 1 infusion liquid
The preparation method of infusion liquid of the present invention: with the needle tubing sucking-off of the air in the packed balanced salt solution, pass into high-purity hydrogen (99.99%), repeated multiple times, with saturated air hydrogen exchange in the liquid.Afterwards with this liquid as for 0.5-0.6MPa(5-6 atmospheric pressure) environment under high pressure under, behind the persistent pressure 4h and can obtain the saturated intraocular irrigating solution of hydrogen.This infusion liquid keeps in Dark Place in 4 ℃, uses under the room temperature.
Among the present invention, the ophthalmology balanced salt solution is ophthalmology balanced salt solution commonly used at present, and the every 1ml of this infusion liquid contains the component of following content:
Solvent is water for injection
Embodiment 2 hydrogen saturated saline solution lumbar injections are intervened the experiment of mice selenium cataract
One, experimental subject
30 of healthy cleaning level 12 age in days SD rat children mouses, body weight 15-20g, male and female hold concurrently half.
Two, experiment reagent
Hydrogen saturated saline solution (self-control), sodium selenite (Tianjin Chemical Plant); SOD testing cassete, CAT testing cassete, GSH testing cassete (bio-engineering research institute is built up in Nanjing).
Three, experimental apparatus
Prosthomere analyser (German Oculus company), operating microscope (Japanese Olympus company), spectrophotometer (U.S. Backman company)
Four, experimental technique
1, model is set up
30 SD rats are divided into Normal group, model control group and hydrogen water treatment group, 10 every group at random.The manufacture method of selenium cataract rat model is: the 12 age in days SD rat children mouse nape subcutaneous injection 2mmol/L of section sodium selenite normal saline (20 μ mol/kg), the next day 1 time, continuous 5 days.Intraperitoneal injection of saline during the Normal group modeling; Model control group when bringing out selenium cataract model, intraperitoneal injection of saline every day (5ml/kg), continuous 5 days; Hydrogen water treatment group when bringing out the selenium cataract, lumbar injection hydrogen saturated saline solution every day (5ml/kg), continuous 5 days.
2, len's opacity is observed
Observed the lenticular muddy degree of each treated animal in rear the 1st, 3,5,7 day respectively at the modeling success.Respectively organize rat at each time point and all adopt compound tropicamide eye drops to carry out the eyes mydriasis, observe the lenticular opacity situation under the slit lamp microscope.
3, biochemical assay is measured SOD, CAT activity and GSH content in the crystalline lens
After successful modeling the 7th day, the cervical vertebra dislocation method is put to death and is respectively organized rat, extracts eyeball, after the normal saline rinsing, cut eyeball at microscopically open from the way of escape, remove wall of eyeball and vitreous body, take out crystalline lens, rear adding PBS weighs, homogenate under the ice-water bath condition, the preparation tissue homogenate, the centrifugal 10min of 1000r/min under 4 ° of C conditions goes supernatant to adopt each test kit to detect SOD, CAT activity and GSH content in the crystalline lens with biochemical assay.
Five, experimental result
The lenticular opacity degree
Rats in normal control group crystalline lens in whole experimentation remains transparent, and the model control group crystalline lens is all fully muddy, and hydrogen water treatment group 45% crystalline lens is fully muddy, and 55% nucleus lentis occurs muddy.Compare with the model matched group, the genesis of hydrogen water treatment group lenticular opacity delays relatively, and muddy degree is starkly lower than model control group (Fig. 2), and wherein: (a) hydrogen water treatment group: the muddiness of slight extent appears in crystalline lens after the modeling success; (b) model control group: crystalline lens is fully muddy after the modeling success; (c) Normal group: crystalline lens is transparent.
Crystalline lens SOD, CAT activity and GSH content detection:
Model control group, hydrogen water treatment group are compared with Normal group, SOD, CAT activity and GSH content all descend to some extent in the crystalline lens, wherein the enzymatic activity of model control group and GSH content decrease are compared with Normal group, and its decline has statistical significance (p＜0.01); And each numerical value of hydrogen water treatment group is compared with Normal group, and its fall does not have statistical significance; Compare with the model matched group, SOD, CAT activity and GSH content obviously increase in the hydrogen water treatment group crystalline lens, and have statistical significance (p＜0.01) (table 1).
From embodiment 2; the experimental result of utilizing hydrogen saturated saline solution lumbar injection to intervene selenium cataract model can be seen; hydrogen water can be protected preferably the active of antioxidase SOD important in the crystalline lens and CAT and keep the content of polyphenoils GSH; thereby prevent crystalline lens generation oxidative damage, delay cataractous generation.
The present invention on this basis, further the hydrogen saturation technique is applied in the preparation process of eye infusion liquid, become the infusion liquid that contains the high concentration of hydrogen molecule so that contain the common eye infusion liquid of higher oxygen content originally, this infusion liquid had both kept the physical characteristic of original eye infusion liquid, in operation, play the effect of perfusion, balance intraocular pressure, eye inner tissue is had no side effect, in intraocular surgery, hydrion in this infusion liquid can free disperse enter cell membrane, with poisonous reactive oxygen species in the cell---hydroxy radical (OH
-) neutralization reaction occurs, directly generate H
2O, thus reduce this material for histiocytic oxidative injury, simultaneously can Cell protection in the content of active and polyphenoils of important antioxidase, by above-mentioned effect, effectively prevent the cataractous generation of postoperative.
Table 1 is that the hydrogen saturated saline solution is intervened superoxide dismutase (SOD), catalase (CAT) activity in the mice selenium cataract crystalline lens, reduced glutathion (GSH) content detection result.
SOD is active in each experimental group rat lens homogenate of table 1, CAT is active, GSH content compares
Annotate: compare with Normal group,
aP＜0.01; Compare with model control group,
bP＜0.01.
Claims (5)
1. an intraocular irrigating solution comprises ophthalmology balanced salt solution medically commonly used, it is characterized in that: the described ophthalmology balanced salt solution of medically commonly using is the saturated intraocular irrigating solution of hydrogen.
2. preparation method that is used for realizing intraocular irrigating solution claimed in claim 1 is characterized in that: said method comprising the steps of:
1) the ophthalmology balanced salt solution of medically commonly using of bag taking dress;
2) with the air in the packed balanced salt solution with aseptic needle tubing from the sucking-off of the soft bag of infusion liquid dosing mouth;
3) slowly pass into high-purity hydrogen until till the soft bag of this infusion liquid is complete expansion, can't passes into unnecessary gaseous state again by pinprick place, aseptic needle tubing place is disposable;
4) the soft bag of sterile sealing infusion liquid dosing mouth;
5) the resulting liquid of step 3) is placed the environment under high pressure persistent pressure of 0.5-0.6Mpa, obtain the saturated intraocular irrigating solution of hydrogen.
3. method according to claim 2, it is characterized in that: high-purity hydrogen is that purity is not less than 99.99% hydrogen in the described step 3).
4. method according to claim 3, it is characterized in that: the time of pressurizeing in the described step 4) is not less than 4 hours.
5. the described method of arbitrary claim according to claim 2-4 is characterized in that: also comprise after the described step 4):
6) place 4 ℃ to keep in Dark Place the saturated intraocular irrigating solution of the resulting hydrogen of step 5).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105458411A CN103006695A (en) | 2012-12-17 | 2012-12-17 | Intraocular perfusate and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105458411A CN103006695A (en) | 2012-12-17 | 2012-12-17 | Intraocular perfusate and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103006695A true CN103006695A (en) | 2013-04-03 |
Family
ID=47956161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012105458411A Pending CN103006695A (en) | 2012-12-17 | 2012-12-17 | Intraocular perfusate and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103006695A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017126708A1 (en) * | 2016-01-21 | 2017-07-27 | 高橋 浩 | Hydrogen molecule-containing prophylactic or therapeutic agent for oxidative stress damages in internal eye surgeries |
| CN109771370A (en) * | 2019-02-28 | 2019-05-21 | 厦门大学 | A kind of intraocular surgery Anterior chamber irrigating solution and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101125149A (en) * | 2007-09-19 | 2008-02-20 | 温州医学院眼视光研究院 | Ophthalmic operating special-purpose colored perfusate |
-
2012
- 2012-12-17 CN CN2012105458411A patent/CN103006695A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101125149A (en) * | 2007-09-19 | 2008-02-20 | 温州医学院眼视光研究院 | Ophthalmic operating special-purpose colored perfusate |
Non-Patent Citations (1)
| Title |
|---|
| IKUROH OHSAWA ET AL: "Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals", 《NATURE MEDICINE》, vol. 13, no. 6, 7 May 2007 (2007-05-07), pages 688 - 694 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017126708A1 (en) * | 2016-01-21 | 2017-07-27 | 高橋 浩 | Hydrogen molecule-containing prophylactic or therapeutic agent for oxidative stress damages in internal eye surgeries |
| CN109771370A (en) * | 2019-02-28 | 2019-05-21 | 厦门大学 | A kind of intraocular surgery Anterior chamber irrigating solution and application thereof |
| WO2020173484A1 (en) * | 2019-02-28 | 2020-09-03 | 厦门大学 | Anterior chamber perfusate for intraocular surgery and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107412258A (en) | It is a kind of that there is the health care eye sticker for alleviating visual fatigue function | |
| CN109431985A (en) | A kind of eye drops and preparation method thereof being used for Dry eye treatment containing excretion body | |
| CN102294053A (en) | Acellular heterogeneous corneal stroma carrier and preparation method and application thereof | |
| CN102100693A (en) | Artificial tears including carnosine and preparation method thereof | |
| CN106215171A (en) | A kind of mesenchymal stem cell injection and its preparation method and application | |
| CN106420809B (en) | A kind of ophthalmologic operation perfusion liquid | |
| CN101416741A (en) | Health-care food for relieving visual fatigue | |
| RU2375016C1 (en) | Method of treating "dry" form of age macular degeneration | |
| CN109771370B (en) | Anterior chamber perfusate for intraocular surgery and application thereof | |
| CN103006695A (en) | Intraocular perfusate and preparation method thereof | |
| CN109528769A (en) | A kind of method for building up of dog cataract model living | |
| CN100522162C (en) | New pranoprofen eye drops and its preparation method | |
| CN105012235B (en) | A kind of ophthalmically acceptable antimycotic nano micellar solution containing terbinafine HCl | |
| CN110025625A (en) | Luteolin -7-O- glucoside or luteolin -7-O- glucuronide are in the application for preparing eye injury drug | |
| CN100455276C (en) | Artificial crystalline humor with surface coated tiatnia film, its prepn and uses | |
| CN111870610B (en) | Application of luteolin-7-O-glucoside in preparation of medicine for treating diseases caused by retinal degeneration | |
| CN101336932B (en) | Freezing powder prepared from low passage pig dermal papilla cells supernatant | |
| CN103054839A (en) | Medicine for killing acid-fast staining positive (red) bacilli | |
| CN107970211B (en) | Preoperative cornea flushing fluid, preparation method and application thereof | |
| CN105999416A (en) | Autologous fat and umbilical cord mesenchymal stem cell composition used for plastic filling | |
| CN104523575B (en) | A kind of hydrobenzole hydrochloride gel for eye and preparation method thereof | |
| CN100360185C (en) | Preparation method of medicine for treating pelada | |
| Hong et al. | Cascade reaction triggering and photothermal AuNPs@ MIL MOFs doped intraocular lens for enhanced posterior capsular opacification prevention | |
| CN100381174C (en) | Preparation method of medicine for treating male baldness and its clinical application | |
| CN106967683A (en) | The method for cultivating pluripotential hemopoietic stem cell |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130403 |